Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave, Labcorp To Co-Develop Companion Dx for Arca Discovery's Heart Failure Drug

NEW YORK (GenomeWeb News) - Third Wave Technologies said today that it will collaborate with Laboratory Corporation of America to develop a diagnostic that may be used in conjunction with a heart failure drug that is being developed by Arca Discovery. 
The diagnostic is intended to help physicians determine use of the drug bucindolol, a beta blocker that Third Wave said could be "the first genetically targeted cardiovascular drug."
The test will be developed in tandem with the drug's approval process, the company added.
Bucindolol has shown "extensive" efficacy and safety in Phase III trials, Third Wave said, noting that Arca plans to use genetic data to target patients most likely to respond to the drug when it seeks FDA approval in 2008.
Labcorp acquired the rights to develop and commercialize the companion diagnostic for the Arca drug in February.
Financial terms of the agreement were not released.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.